nodes	percent_of_prediction	percent_of_DWPC	metapath
Vidarabine—Cytarabine—Gemcitabine—lung cancer	0.229	0.35	CrCrCtD
Vidarabine—Azacitidine—Gemcitabine—lung cancer	0.218	0.333	CrCrCtD
Vidarabine—Decitabine—Gemcitabine—lung cancer	0.207	0.317	CrCrCtD
Vidarabine—ADA—pleura—lung cancer	0.04	0.518	CbGeAlD
Vidarabine—ADK—mammary gland—lung cancer	0.00487	0.063	CbGeAlD
Vidarabine—ADA—respiratory system—lung cancer	0.00397	0.0514	CbGeAlD
Vidarabine—DPP4—respiratory system—lung cancer	0.00315	0.0407	CbGeAlD
Vidarabine—ADK—bronchus—lung cancer	0.00267	0.0346	CbGeAlD
Vidarabine—DPP4—epithelium—lung cancer	0.00263	0.034	CbGeAlD
Vidarabine—ADK—trachea—lung cancer	0.0024	0.031	CbGeAlD
Vidarabine—ADA—bone marrow—lung cancer	0.00233	0.0301	CbGeAlD
Vidarabine—ADK—cardiac atrium—lung cancer	0.00225	0.0292	CbGeAlD
Vidarabine—ADA—lung—lung cancer	0.00211	0.0273	CbGeAlD
Vidarabine—ADK—bone marrow—lung cancer	0.0019	0.0246	CbGeAlD
Vidarabine—DPP4—bone marrow—lung cancer	0.00184	0.0239	CbGeAlD
Vidarabine—ADK—lung—lung cancer	0.00172	0.0223	CbGeAlD
Vidarabine—DPP4—lung—lung cancer	0.00167	0.0216	CbGeAlD
Vidarabine—Adenosine monophosphate—ADCY1—lung cancer	0.00151	0.176	CrCbGaD
Vidarabine—ADA—lymph node—lung cancer	0.00144	0.0187	CbGeAlD
Vidarabine—Adenosine triphosphate—ADCY1—lung cancer	0.00131	0.152	CrCbGaD
Vidarabine—Clofarabine—RRM1—lung cancer	0.00119	0.139	CrCbGaD
Vidarabine—ADK—lymph node—lung cancer	0.00118	0.0153	CbGeAlD
Vidarabine—Fludarabine—RRM1—lung cancer	0.00116	0.135	CrCbGaD
Vidarabine—DPP4—lymph node—lung cancer	0.00114	0.0148	CbGeAlD
Vidarabine—Cladribine—RRM1—lung cancer	0.000686	0.08	CrCbGaD
Vidarabine—Glucosamine—MMP9—lung cancer	0.000551	0.0643	CrCbGaD
Vidarabine—Adenosine triphosphate—ALK—lung cancer	0.000454	0.053	CrCbGaD
Vidarabine—Adenosine triphosphate—AKT1—lung cancer	0.000355	0.0414	CrCbGaD
Vidarabine—Adenosine monophosphate—SRC—lung cancer	0.00035	0.0408	CrCbGaD
Vidarabine—Clofarabine—ABCG2—lung cancer	0.000305	0.0356	CrCbGaD
Vidarabine—Glucosamine—CYP2E1—lung cancer	0.000279	0.0326	CrCbGaD
Vidarabine—Chest pain—Gemcitabine—lung cancer	0.000214	0.00124	CcSEcCtD
Vidarabine—Asthenia—Erlotinib—lung cancer	0.000212	0.00123	CcSEcCtD
Vidarabine—Discomfort—Gemcitabine—lung cancer	0.000212	0.00123	CcSEcCtD
Vidarabine—Anaphylactic shock—Irinotecan—lung cancer	0.000211	0.00122	CcSEcCtD
Vidarabine—Dysgeusia—Etoposide—lung cancer	0.00021	0.00122	CcSEcCtD
Vidarabine—Back pain—Etoposide—lung cancer	0.000208	0.00121	CcSEcCtD
Vidarabine—Shock—Irinotecan—lung cancer	0.000207	0.0012	CcSEcCtD
Vidarabine—Tension—Paclitaxel—lung cancer	0.000207	0.0012	CcSEcCtD
Vidarabine—Dysgeusia—Paclitaxel—lung cancer	0.000206	0.0012	CcSEcCtD
Vidarabine—Anaphylactic shock—Gemcitabine—lung cancer	0.000205	0.00119	CcSEcCtD
Vidarabine—Nervousness—Paclitaxel—lung cancer	0.000205	0.00119	CcSEcCtD
Vidarabine—Hypoaesthesia—Docetaxel—lung cancer	0.000204	0.00119	CcSEcCtD
Vidarabine—Hyperhidrosis—Irinotecan—lung cancer	0.000204	0.00118	CcSEcCtD
Vidarabine—Back pain—Paclitaxel—lung cancer	0.000204	0.00118	CcSEcCtD
Vidarabine—Dizziness—Vinblastine—lung cancer	0.000203	0.00118	CcSEcCtD
Vidarabine—Convulsion—Cisplatin—lung cancer	0.000203	0.00118	CcSEcCtD
Vidarabine—Urticaria—Vinorelbine—lung cancer	0.000203	0.00118	CcSEcCtD
Vidarabine—Mood swings—Methotrexate—lung cancer	0.000202	0.00118	CcSEcCtD
Vidarabine—Anxiety—Cisplatin—lung cancer	0.000199	0.00116	CcSEcCtD
Vidarabine—Vision blurred—Paclitaxel—lung cancer	0.000198	0.00115	CcSEcCtD
Vidarabine—Hyperhidrosis—Gemcitabine—lung cancer	0.000198	0.00115	CcSEcCtD
Vidarabine—Dizziness—Topotecan—lung cancer	0.000198	0.00115	CcSEcCtD
Vidarabine—Tremor—Paclitaxel—lung cancer	0.000197	0.00115	CcSEcCtD
Vidarabine—Discomfort—Cisplatin—lung cancer	0.000197	0.00115	CcSEcCtD
Vidarabine—Hypotension—Irinotecan—lung cancer	0.000197	0.00114	CcSEcCtD
Vidarabine—Vomiting—Vinblastine—lung cancer	0.000196	0.00114	CcSEcCtD
Vidarabine—Dizziness—Erlotinib—lung cancer	0.000195	0.00114	CcSEcCtD
Vidarabine—Agitation—Paclitaxel—lung cancer	0.000194	0.00112	CcSEcCtD
Vidarabine—Headache—Vinblastine—lung cancer	0.000193	0.00112	CcSEcCtD
Vidarabine—Angioedema—Paclitaxel—lung cancer	0.000192	0.00112	CcSEcCtD
Vidarabine—Hypotension—Gemcitabine—lung cancer	0.000192	0.00111	CcSEcCtD
Vidarabine—Anaphylactic shock—Cisplatin—lung cancer	0.000191	0.00111	CcSEcCtD
Vidarabine—S-Adenosylmethionine—CYP2E1—lung cancer	0.000191	0.0223	CrCbGaD
Vidarabine—Cardiac disorder—Docetaxel—lung cancer	0.00019	0.00111	CcSEcCtD
Vidarabine—Flushing—Docetaxel—lung cancer	0.00019	0.00111	CcSEcCtD
Vidarabine—Vomiting—Topotecan—lung cancer	0.00019	0.0011	CcSEcCtD
Vidarabine—Cardiac failure—Doxorubicin—lung cancer	0.00019	0.0011	CcSEcCtD
Vidarabine—Paraesthesia—Irinotecan—lung cancer	0.000189	0.0011	CcSEcCtD
Vidarabine—Syncope—Paclitaxel—lung cancer	0.000189	0.0011	CcSEcCtD
Vidarabine—Loss of consciousness—Etoposide—lung cancer	0.000189	0.0011	CcSEcCtD
Vidarabine—Cerebrovascular accident—Doxorubicin—lung cancer	0.000189	0.0011	CcSEcCtD
Vidarabine—Rash—Topotecan—lung cancer	0.000188	0.00109	CcSEcCtD
Vidarabine—Hypersensitivity—Vinorelbine—lung cancer	0.000188	0.00109	CcSEcCtD
Vidarabine—Dermatitis—Topotecan—lung cancer	0.000188	0.00109	CcSEcCtD
Vidarabine—Vomiting—Erlotinib—lung cancer	0.000188	0.00109	CcSEcCtD
Vidarabine—Dyspnoea—Irinotecan—lung cancer	0.000188	0.00109	CcSEcCtD
Vidarabine—Cough—Etoposide—lung cancer	0.000187	0.00109	CcSEcCtD
Vidarabine—Somnolence—Irinotecan—lung cancer	0.000187	0.00109	CcSEcCtD
Vidarabine—Headache—Topotecan—lung cancer	0.000187	0.00109	CcSEcCtD
Vidarabine—Musculoskeletal discomfort—Gemcitabine—lung cancer	0.000187	0.00109	CcSEcCtD
Vidarabine—Tachycardia—Cisplatin—lung cancer	0.000187	0.00109	CcSEcCtD
Vidarabine—Rash—Erlotinib—lung cancer	0.000186	0.00108	CcSEcCtD
Vidarabine—Dermatitis—Erlotinib—lung cancer	0.000186	0.00108	CcSEcCtD
Vidarabine—Palpitations—Paclitaxel—lung cancer	0.000186	0.00108	CcSEcCtD
Vidarabine—Convulsion—Etoposide—lung cancer	0.000186	0.00108	CcSEcCtD
Vidarabine—Hypertension—Etoposide—lung cancer	0.000185	0.00108	CcSEcCtD
Vidarabine—Headache—Erlotinib—lung cancer	0.000185	0.00108	CcSEcCtD
Vidarabine—Loss of consciousness—Paclitaxel—lung cancer	0.000185	0.00108	CcSEcCtD
Vidarabine—Hyperhidrosis—Cisplatin—lung cancer	0.000185	0.00107	CcSEcCtD
Vidarabine—Mediastinal disorder—Docetaxel—lung cancer	0.000185	0.00107	CcSEcCtD
Vidarabine—Paraesthesia—Gemcitabine—lung cancer	0.000184	0.00107	CcSEcCtD
Vidarabine—Cough—Paclitaxel—lung cancer	0.000184	0.00107	CcSEcCtD
Vidarabine—Asthenia—Vinorelbine—lung cancer	0.000183	0.00107	CcSEcCtD
Vidarabine—Arrhythmia—Docetaxel—lung cancer	0.000183	0.00106	CcSEcCtD
Vidarabine—Dyspnoea—Gemcitabine—lung cancer	0.000183	0.00106	CcSEcCtD
Vidarabine—Chest pain—Etoposide—lung cancer	0.000183	0.00106	CcSEcCtD
Vidarabine—Nausea—Vinblastine—lung cancer	0.000183	0.00106	CcSEcCtD
Vidarabine—Somnolence—Gemcitabine—lung cancer	0.000183	0.00106	CcSEcCtD
Vidarabine—Convulsion—Paclitaxel—lung cancer	0.000182	0.00106	CcSEcCtD
Vidarabine—Affect lability—Doxorubicin—lung cancer	0.000182	0.00106	CcSEcCtD
Vidarabine—Hypertension—Paclitaxel—lung cancer	0.000182	0.00106	CcSEcCtD
Vidarabine—Discomfort—Etoposide—lung cancer	0.000181	0.00105	CcSEcCtD
Vidarabine—Pain—Irinotecan—lung cancer	0.00018	0.00105	CcSEcCtD
Vidarabine—Chest pain—Paclitaxel—lung cancer	0.000179	0.00104	CcSEcCtD
Vidarabine—Hypotension—Cisplatin—lung cancer	0.000179	0.00104	CcSEcCtD
Vidarabine—Anxiety—Paclitaxel—lung cancer	0.000179	0.00104	CcSEcCtD
Vidarabine—Nausea—Topotecan—lung cancer	0.000177	0.00103	CcSEcCtD
Vidarabine—Discomfort—Paclitaxel—lung cancer	0.000177	0.00103	CcSEcCtD
Vidarabine—Abdominal discomfort—Methotrexate—lung cancer	0.000177	0.00103	CcSEcCtD
Vidarabine—Cardiac arrest—Doxorubicin—lung cancer	0.000176	0.00102	CcSEcCtD
Vidarabine—Pain—Gemcitabine—lung cancer	0.000176	0.00102	CcSEcCtD
Vidarabine—Nausea—Erlotinib—lung cancer	0.000176	0.00102	CcSEcCtD
Vidarabine—Dry mouth—Paclitaxel—lung cancer	0.000175	0.00102	CcSEcCtD
Vidarabine—Anaphylactic shock—Etoposide—lung cancer	0.000175	0.00102	CcSEcCtD
Vidarabine—Mood swings—Doxorubicin—lung cancer	0.000175	0.00102	CcSEcCtD
Vidarabine—Cladribine—ABCG2—lung cancer	0.000175	0.0204	CrCbGaD
Vidarabine—Dysgeusia—Docetaxel—lung cancer	0.000175	0.00102	CcSEcCtD
Vidarabine—Musculoskeletal discomfort—Cisplatin—lung cancer	0.000174	0.00101	CcSEcCtD
Vidarabine—Back pain—Docetaxel—lung cancer	0.000173	0.001	CcSEcCtD
Vidarabine—Anaphylactic shock—Paclitaxel—lung cancer	0.000172	0.000999	CcSEcCtD
Vidarabine—Paraesthesia—Cisplatin—lung cancer	0.000172	0.000998	CcSEcCtD
Vidarabine—Tachycardia—Etoposide—lung cancer	0.000171	0.000994	CcSEcCtD
Vidarabine—Dyspnoea—Cisplatin—lung cancer	0.000171	0.000991	CcSEcCtD
Vidarabine—Hyperhidrosis—Etoposide—lung cancer	0.000169	0.000985	CcSEcCtD
Vidarabine—Shock—Paclitaxel—lung cancer	0.000169	0.000983	CcSEcCtD
Vidarabine—Dizziness—Vinorelbine—lung cancer	0.000169	0.000982	CcSEcCtD
Vidarabine—Tachycardia—Paclitaxel—lung cancer	0.000168	0.000975	CcSEcCtD
Vidarabine—Hyperhidrosis—Paclitaxel—lung cancer	0.000166	0.000965	CcSEcCtD
Vidarabine—Drowsiness—Methotrexate—lung cancer	0.000165	0.000957	CcSEcCtD
Vidarabine—Hypotension—Etoposide—lung cancer	0.000164	0.000952	CcSEcCtD
Vidarabine—Pain—Cisplatin—lung cancer	0.000164	0.000951	CcSEcCtD
Vidarabine—Vomiting—Vinorelbine—lung cancer	0.000162	0.000944	CcSEcCtD
Vidarabine—Rash—Vinorelbine—lung cancer	0.000161	0.000936	CcSEcCtD
Vidarabine—Dermatitis—Vinorelbine—lung cancer	0.000161	0.000935	CcSEcCtD
Vidarabine—Hypotension—Paclitaxel—lung cancer	0.000161	0.000933	CcSEcCtD
Vidarabine—Headache—Vinorelbine—lung cancer	0.00016	0.00093	CcSEcCtD
Vidarabine—Syncope—Docetaxel—lung cancer	0.00016	0.00093	CcSEcCtD
Vidarabine—Sweating—Methotrexate—lung cancer	0.000158	0.000917	CcSEcCtD
Vidarabine—Palpitations—Docetaxel—lung cancer	0.000158	0.000917	CcSEcCtD
Vidarabine—Paraesthesia—Etoposide—lung cancer	0.000157	0.000915	CcSEcCtD
Vidarabine—Loss of consciousness—Docetaxel—lung cancer	0.000157	0.000912	CcSEcCtD
Vidarabine—Musculoskeletal discomfort—Paclitaxel—lung cancer	0.000157	0.00091	CcSEcCtD
Vidarabine—Dyspnoea—Etoposide—lung cancer	0.000156	0.000908	CcSEcCtD
Vidarabine—Somnolence—Etoposide—lung cancer	0.000156	0.000906	CcSEcCtD
Vidarabine—Cough—Docetaxel—lung cancer	0.000156	0.000905	CcSEcCtD
Vidarabine—Hypersensitivity—Irinotecan—lung cancer	0.000155	0.000902	CcSEcCtD
Vidarabine—Convulsion—Docetaxel—lung cancer	0.000155	0.000899	CcSEcCtD
Vidarabine—Paraesthesia—Paclitaxel—lung cancer	0.000154	0.000897	CcSEcCtD
Vidarabine—Hypertension—Docetaxel—lung cancer	0.000154	0.000895	CcSEcCtD
Vidarabine—Dyspnoea—Paclitaxel—lung cancer	0.000153	0.00089	CcSEcCtD
Vidarabine—Somnolence—Paclitaxel—lung cancer	0.000153	0.000888	CcSEcCtD
Vidarabine—Chest pain—Docetaxel—lung cancer	0.000152	0.000883	CcSEcCtD
Vidarabine—Nausea—Vinorelbine—lung cancer	0.000152	0.000882	CcSEcCtD
Vidarabine—Asthenia—Irinotecan—lung cancer	0.000151	0.000879	CcSEcCtD
Vidarabine—Pain—Etoposide—lung cancer	0.00015	0.000871	CcSEcCtD
Vidarabine—Dry mouth—Docetaxel—lung cancer	0.000149	0.000864	CcSEcCtD
Vidarabine—Pollakiuria—Doxorubicin—lung cancer	0.000148	0.000858	CcSEcCtD
Vidarabine—Asthenia—Gemcitabine—lung cancer	0.000147	0.000856	CcSEcCtD
Vidarabine—Pain—Paclitaxel—lung cancer	0.000147	0.000854	CcSEcCtD
Vidarabine—Anaphylactic shock—Docetaxel—lung cancer	0.000146	0.000846	CcSEcCtD
Vidarabine—Shock—Docetaxel—lung cancer	0.000143	0.000833	CcSEcCtD
Vidarabine—Drowsiness—Doxorubicin—lung cancer	0.000143	0.000828	CcSEcCtD
Vidarabine—Tachycardia—Docetaxel—lung cancer	0.000142	0.000826	CcSEcCtD
Vidarabine—Hypersensitivity—Cisplatin—lung cancer	0.000141	0.000819	CcSEcCtD
Vidarabine—Dizziness—Irinotecan—lung cancer	0.000139	0.00081	CcSEcCtD
Vidarabine—Urticaria—Etoposide—lung cancer	0.000139	0.000809	CcSEcCtD
Vidarabine—Tinnitus—Methotrexate—lung cancer	0.000138	0.000801	CcSEcCtD
Vidarabine—Asthenia—Cisplatin—lung cancer	0.000137	0.000798	CcSEcCtD
Vidarabine—Cardiac disorder—Methotrexate—lung cancer	0.000137	0.000797	CcSEcCtD
Vidarabine—Sweating—Doxorubicin—lung cancer	0.000137	0.000794	CcSEcCtD
Vidarabine—Urticaria—Paclitaxel—lung cancer	0.000137	0.000793	CcSEcCtD
Vidarabine—Hypotension—Docetaxel—lung cancer	0.000136	0.000791	CcSEcCtD
Vidarabine—Vomiting—Irinotecan—lung cancer	0.000134	0.000779	CcSEcCtD
Vidarabine—Mediastinal disorder—Methotrexate—lung cancer	0.000133	0.000774	CcSEcCtD
Vidarabine—Rash—Irinotecan—lung cancer	0.000133	0.000772	CcSEcCtD
Vidarabine—Dermatitis—Irinotecan—lung cancer	0.000133	0.000771	CcSEcCtD
Vidarabine—Musculoskeletal discomfort—Docetaxel—lung cancer	0.000133	0.000771	CcSEcCtD
Vidarabine—Headache—Irinotecan—lung cancer	0.000132	0.000767	CcSEcCtD
Vidarabine—Paraesthesia—Docetaxel—lung cancer	0.000131	0.00076	CcSEcCtD
Vidarabine—Vomiting—Gemcitabine—lung cancer	0.000131	0.000758	CcSEcCtD
Vidarabine—Bradycardia—Doxorubicin—lung cancer	0.00013	0.000757	CcSEcCtD
Vidarabine—Dyspnoea—Docetaxel—lung cancer	0.00013	0.000755	CcSEcCtD
Vidarabine—Somnolence—Docetaxel—lung cancer	0.00013	0.000753	CcSEcCtD
Vidarabine—Rash—Gemcitabine—lung cancer	0.000129	0.000752	CcSEcCtD
Vidarabine—Dermatitis—Gemcitabine—lung cancer	0.000129	0.000751	CcSEcCtD
Vidarabine—Hypersensitivity—Etoposide—lung cancer	0.000129	0.00075	CcSEcCtD
Vidarabine—Headache—Gemcitabine—lung cancer	0.000129	0.000747	CcSEcCtD
Vidarabine—Hypoaesthesia—Doxorubicin—lung cancer	0.000127	0.00074	CcSEcCtD
Vidarabine—Hypersensitivity—Paclitaxel—lung cancer	0.000127	0.000736	CcSEcCtD
Vidarabine—Dysgeusia—Methotrexate—lung cancer	0.000126	0.000732	CcSEcCtD
Vidarabine—Asthenia—Etoposide—lung cancer	0.000126	0.000731	CcSEcCtD
Vidarabine—Nausea—Irinotecan—lung cancer	0.000125	0.000727	CcSEcCtD
Vidarabine—Pain—Docetaxel—lung cancer	0.000125	0.000724	CcSEcCtD
Vidarabine—Back pain—Methotrexate—lung cancer	0.000124	0.000723	CcSEcCtD
Vidarabine—Asthenia—Paclitaxel—lung cancer	0.000123	0.000717	CcSEcCtD
Vidarabine—Nausea—Gemcitabine—lung cancer	0.000122	0.000709	CcSEcCtD
Vidarabine—Vomiting—Cisplatin—lung cancer	0.000122	0.000707	CcSEcCtD
Vidarabine—Vision blurred—Methotrexate—lung cancer	0.000121	0.000705	CcSEcCtD
Vidarabine—Rash—Cisplatin—lung cancer	0.000121	0.000701	CcSEcCtD
Vidarabine—Dermatitis—Cisplatin—lung cancer	0.000121	0.0007	CcSEcCtD
Vidarabine—Tinnitus—Doxorubicin—lung cancer	0.000119	0.000693	CcSEcCtD
Vidarabine—Flushing—Doxorubicin—lung cancer	0.000119	0.00069	CcSEcCtD
Vidarabine—Cardiac disorder—Doxorubicin—lung cancer	0.000119	0.00069	CcSEcCtD
Vidarabine—Dizziness—Etoposide—lung cancer	0.000116	0.000674	CcSEcCtD
Vidarabine—Mediastinal disorder—Doxorubicin—lung cancer	0.000115	0.00067	CcSEcCtD
Vidarabine—Arrhythmia—Doxorubicin—lung cancer	0.000114	0.000664	CcSEcCtD
Vidarabine—Dizziness—Paclitaxel—lung cancer	0.000114	0.00066	CcSEcCtD
Vidarabine—Nausea—Cisplatin—lung cancer	0.000114	0.00066	CcSEcCtD
Vidarabine—ADK—Metabolism—CYP2A6—lung cancer	0.000113	0.00128	CbGpPWpGaD
Vidarabine—Cough—Methotrexate—lung cancer	0.000112	0.000652	CcSEcCtD
Vidarabine—ADORA2A—Signaling by GPCR—GIPR—lung cancer	0.000112	0.00127	CbGpPWpGaD
Vidarabine—Convulsion—Methotrexate—lung cancer	0.000111	0.000648	CcSEcCtD
Vidarabine—Vomiting—Etoposide—lung cancer	0.000111	0.000648	CcSEcCtD
Vidarabine—Rash—Etoposide—lung cancer	0.000111	0.000642	CcSEcCtD
Vidarabine—Dermatitis—Etoposide—lung cancer	0.00011	0.000642	CcSEcCtD
Vidarabine—ADA—Metabolism—B4GALT5—lung cancer	0.00011	0.00125	CbGpPWpGaD
Vidarabine—Headache—Etoposide—lung cancer	0.00011	0.000638	CcSEcCtD
Vidarabine—Chest pain—Methotrexate—lung cancer	0.00011	0.000636	CcSEcCtD
Vidarabine—Tension—Doxorubicin—lung cancer	0.000109	0.000635	CcSEcCtD
Vidarabine—Vomiting—Paclitaxel—lung cancer	0.000109	0.000635	CcSEcCtD
Vidarabine—Dysgeusia—Doxorubicin—lung cancer	0.000109	0.000634	CcSEcCtD
Vidarabine—ADORA2A—Class A/1 (Rhodopsin-like receptors)—AVP—lung cancer	0.000109	0.00124	CbGpPWpGaD
Vidarabine—Rash—Paclitaxel—lung cancer	0.000108	0.00063	CcSEcCtD
Vidarabine—Dermatitis—Paclitaxel—lung cancer	0.000108	0.000629	CcSEcCtD
Vidarabine—Discomfort—Methotrexate—lung cancer	0.000108	0.000629	CcSEcCtD
Vidarabine—Nervousness—Doxorubicin—lung cancer	0.000108	0.000629	CcSEcCtD
Vidarabine—Back pain—Doxorubicin—lung cancer	0.000108	0.000626	CcSEcCtD
Vidarabine—Headache—Paclitaxel—lung cancer	0.000108	0.000626	CcSEcCtD
Vidarabine—ADA—Metabolism—GSTA4—lung cancer	0.000107	0.00122	CbGpPWpGaD
Vidarabine—Hypersensitivity—Docetaxel—lung cancer	0.000107	0.000624	CcSEcCtD
Vidarabine—ADORA2A—GPCR ligand binding—APP—lung cancer	0.000107	0.00121	CbGpPWpGaD
Vidarabine—ADK—Metabolism—ENO1—lung cancer	0.000107	0.00121	CbGpPWpGaD
Vidarabine—ADORA2A—NGF signalling via TRKA from the plasma membrane—KIT—lung cancer	0.000106	0.00121	CbGpPWpGaD
Vidarabine—ADORA2A—NGF signalling via TRKA from the plasma membrane—EGF—lung cancer	0.000105	0.00119	CbGpPWpGaD
Vidarabine—ADORA2A—GPCR downstream signaling—GRM8—lung cancer	0.000105	0.00119	CbGpPWpGaD
Vidarabine—Anaphylactic shock—Methotrexate—lung cancer	0.000105	0.00061	CcSEcCtD
Vidarabine—Vision blurred—Doxorubicin—lung cancer	0.000105	0.00061	CcSEcCtD
Vidarabine—ADA—Metabolism—GSTA2—lung cancer	0.000105	0.00119	CbGpPWpGaD
Vidarabine—Asthenia—Docetaxel—lung cancer	0.000105	0.000607	CcSEcCtD
Vidarabine—Nausea—Etoposide—lung cancer	0.000104	0.000605	CcSEcCtD
Vidarabine—Agitation—Doxorubicin—lung cancer	0.000102	0.000595	CcSEcCtD
Vidarabine—Nausea—Paclitaxel—lung cancer	0.000102	0.000593	CcSEcCtD
Vidarabine—Hyperhidrosis—Methotrexate—lung cancer	0.000102	0.00059	CcSEcCtD
Vidarabine—ADORA2A—Signaling by NGF—ERBB3—lung cancer	0.000101	0.00115	CbGpPWpGaD
Vidarabine—ADA—Metabolism—GSTA1—lung cancer	0.000101	0.00114	CbGpPWpGaD
Vidarabine—ADORA2A—NGF signalling via TRKA from the plasma membrane—BRAF—lung cancer	0.0001	0.00113	CbGpPWpGaD
Vidarabine—Syncope—Doxorubicin—lung cancer	9.99e-05	0.00058	CcSEcCtD
Vidarabine—ADA—Metabolism—ABCC3—lung cancer	9.98e-05	0.00113	CbGpPWpGaD
Vidarabine—ADORA2A—NGF signalling via TRKA from the plasma membrane—IL6R—lung cancer	9.88e-05	0.00112	CbGpPWpGaD
Vidarabine—Palpitations—Doxorubicin—lung cancer	9.85e-05	0.000572	CcSEcCtD
Vidarabine—Hypotension—Methotrexate—lung cancer	9.81e-05	0.00057	CcSEcCtD
Vidarabine—Loss of consciousness—Doxorubicin—lung cancer	9.79e-05	0.000569	CcSEcCtD
Vidarabine—DPP4—Metabolism of proteins—MMP1—lung cancer	9.75e-05	0.00111	CbGpPWpGaD
Vidarabine—Cough—Doxorubicin—lung cancer	9.72e-05	0.000565	CcSEcCtD
Vidarabine—ADA—Metabolism—AKR1C1—lung cancer	9.67e-05	0.0011	CbGpPWpGaD
Vidarabine—Convulsion—Doxorubicin—lung cancer	9.65e-05	0.000561	CcSEcCtD
Vidarabine—Dizziness—Docetaxel—lung cancer	9.63e-05	0.00056	CcSEcCtD
Vidarabine—Hypertension—Doxorubicin—lung cancer	9.62e-05	0.000559	CcSEcCtD
Vidarabine—ADK—Metabolism—CYP2E1—lung cancer	9.57e-05	0.00108	CbGpPWpGaD
Vidarabine—Musculoskeletal discomfort—Methotrexate—lung cancer	9.57e-05	0.000556	CcSEcCtD
Vidarabine—ADORA2A—Signaling by GPCR—GRM8—lung cancer	9.54e-05	0.00108	CbGpPWpGaD
Vidarabine—Chest pain—Doxorubicin—lung cancer	9.49e-05	0.000551	CcSEcCtD
Vidarabine—ADK—Metabolism—NQO1—lung cancer	9.46e-05	0.00107	CbGpPWpGaD
Vidarabine—Anxiety—Doxorubicin—lung cancer	9.45e-05	0.000549	CcSEcCtD
Vidarabine—ADORA2A—Signaling by NGF—FGFR1—lung cancer	9.43e-05	0.00107	CbGpPWpGaD
Vidarabine—Paraesthesia—Methotrexate—lung cancer	9.43e-05	0.000548	CcSEcCtD
Vidarabine—ADORA2A—NGF signalling via TRKA from the plasma membrane—MAP2K1—lung cancer	9.42e-05	0.00107	CbGpPWpGaD
Vidarabine—ADA—Metabolism—UGT1A1—lung cancer	9.38e-05	0.00106	CbGpPWpGaD
Vidarabine—Discomfort—Doxorubicin—lung cancer	9.37e-05	0.000544	CcSEcCtD
Vidarabine—Dyspnoea—Methotrexate—lung cancer	9.36e-05	0.000544	CcSEcCtD
Vidarabine—ADORA2A—NGF signalling via TRKA from the plasma membrane—PIK3CD—lung cancer	9.36e-05	0.00106	CbGpPWpGaD
Vidarabine—Somnolence—Methotrexate—lung cancer	9.34e-05	0.000542	CcSEcCtD
Vidarabine—Dry mouth—Doxorubicin—lung cancer	9.28e-05	0.000539	CcSEcCtD
Vidarabine—Vomiting—Docetaxel—lung cancer	9.26e-05	0.000538	CcSEcCtD
Vidarabine—Rash—Docetaxel—lung cancer	9.19e-05	0.000534	CcSEcCtD
Vidarabine—Dermatitis—Docetaxel—lung cancer	9.18e-05	0.000533	CcSEcCtD
Vidarabine—Headache—Docetaxel—lung cancer	9.13e-05	0.00053	CcSEcCtD
Vidarabine—Anaphylactic shock—Doxorubicin—lung cancer	9.09e-05	0.000528	CcSEcCtD
Vidarabine—ADA—Metabolism—GNG11—lung cancer	9.05e-05	0.00103	CbGpPWpGaD
Vidarabine—Pain—Methotrexate—lung cancer	8.98e-05	0.000522	CcSEcCtD
Vidarabine—Shock—Doxorubicin—lung cancer	8.95e-05	0.00052	CcSEcCtD
Vidarabine—Tachycardia—Doxorubicin—lung cancer	8.87e-05	0.000516	CcSEcCtD
Vidarabine—Hyperhidrosis—Doxorubicin—lung cancer	8.79e-05	0.000511	CcSEcCtD
Vidarabine—ADORA2A—Signaling Pathways—AXL—lung cancer	8.75e-05	0.000991	CbGpPWpGaD
Vidarabine—ADORA2A—GPCR downstream signaling—GRP—lung cancer	8.65e-05	0.000981	CbGpPWpGaD
Vidarabine—ADORA2A—GPCR downstream signaling—OXTR—lung cancer	8.65e-05	0.000981	CbGpPWpGaD
Vidarabine—Nausea—Docetaxel—lung cancer	8.65e-05	0.000503	CcSEcCtD
Vidarabine—ADA—Metabolism—ALDOA—lung cancer	8.62e-05	0.000976	CbGpPWpGaD
Vidarabine—ADA—Circadian rythm related genes—TP53—lung cancer	8.54e-05	0.000968	CbGpPWpGaD
Vidarabine—ADK—Metabolism—STK11—lung cancer	8.53e-05	0.000967	CbGpPWpGaD
Vidarabine—Hypotension—Doxorubicin—lung cancer	8.5e-05	0.000494	CcSEcCtD
Vidarabine—ADORA2A—NGF signalling via TRKA from the plasma membrane—MDM2—lung cancer	8.38e-05	0.00095	CbGpPWpGaD
Vidarabine—ADA—Metabolism—NCOA3—lung cancer	8.36e-05	0.000948	CbGpPWpGaD
Vidarabine—ADORA2A—NGF signalling via TRKA from the plasma membrane—RAF1—lung cancer	8.35e-05	0.000946	CbGpPWpGaD
Vidarabine—Urticaria—Methotrexate—lung cancer	8.34e-05	0.000485	CcSEcCtD
Vidarabine—ADORA2A—GPCR ligand binding—AVP—lung cancer	8.31e-05	0.000941	CbGpPWpGaD
Vidarabine—Musculoskeletal discomfort—Doxorubicin—lung cancer	8.28e-05	0.000481	CcSEcCtD
Vidarabine—ADORA2A—NGF signalling via TRKA from the plasma membrane—ERBB2—lung cancer	8.26e-05	0.000936	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by NGF—KIT—lung cancer	8.19e-05	0.000928	CbGpPWpGaD
Vidarabine—Paraesthesia—Doxorubicin—lung cancer	8.16e-05	0.000474	CcSEcCtD
Vidarabine—ADORA2A—NGF signalling via TRKA from the plasma membrane—MTOR—lung cancer	8.15e-05	0.000924	CbGpPWpGaD
Vidarabine—ADORA2A—NGF signalling via TRKA from the plasma membrane—PIK3CB—lung cancer	8.15e-05	0.000924	CbGpPWpGaD
Vidarabine—ADA—Metabolism—ADCY1—lung cancer	8.14e-05	0.000922	CbGpPWpGaD
Vidarabine—ADA—Metabolism—ABCG2—lung cancer	8.14e-05	0.000922	CbGpPWpGaD
Vidarabine—DPP4—Metabolism of proteins—POMC—lung cancer	8.11e-05	0.000919	CbGpPWpGaD
Vidarabine—Dyspnoea—Doxorubicin—lung cancer	8.11e-05	0.000471	CcSEcCtD
Vidarabine—ADORA2A—GPCR downstream signaling—GNG11—lung cancer	8.1e-05	0.000918	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by NGF—EGF—lung cancer	8.09e-05	0.000917	CbGpPWpGaD
Vidarabine—Somnolence—Doxorubicin—lung cancer	8.08e-05	0.00047	CcSEcCtD
Vidarabine—ADA—Metabolism—ENO2—lung cancer	7.98e-05	0.000904	CbGpPWpGaD
Vidarabine—ADA—Metabolism—HPGDS—lung cancer	7.98e-05	0.000904	CbGpPWpGaD
Vidarabine—ADA—Metabolism—PPP2R1B—lung cancer	7.93e-05	0.000899	CbGpPWpGaD
Vidarabine—ADK—Metabolism—GSTP1—lung cancer	7.89e-05	0.000894	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by GPCR—OXTR—lung cancer	7.86e-05	0.000891	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by GPCR—GRP—lung cancer	7.86e-05	0.000891	CbGpPWpGaD
Vidarabine—ADA—Circadian rythm related genes—IL6—lung cancer	7.82e-05	0.000886	CbGpPWpGaD
Vidarabine—Pain—Doxorubicin—lung cancer	7.78e-05	0.000452	CcSEcCtD
Vidarabine—ADA—Metabolism—GSTT1—lung cancer	7.74e-05	0.000877	CbGpPWpGaD
Vidarabine—Hypersensitivity—Methotrexate—lung cancer	7.74e-05	0.000449	CcSEcCtD
Vidarabine—ADORA2A—Signaling by NGF—BRAF—lung cancer	7.69e-05	0.000872	CbGpPWpGaD
Vidarabine—ADK—Metabolism—CAT—lung cancer	7.68e-05	0.00087	CbGpPWpGaD
Vidarabine—ADA—Metabolism—GCLC—lung cancer	7.65e-05	0.000867	CbGpPWpGaD
Vidarabine—ADA—Metabolism—CYP2A6—lung cancer	7.65e-05	0.000867	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by NGF—IL6R—lung cancer	7.6e-05	0.000861	CbGpPWpGaD
Vidarabine—DPP4—Metabolism of proteins—MMP2—lung cancer	7.55e-05	0.000855	CbGpPWpGaD
Vidarabine—Asthenia—Methotrexate—lung cancer	7.53e-05	0.000438	CcSEcCtD
Vidarabine—ADK—Metabolism—ABCB1—lung cancer	7.47e-05	0.000847	CbGpPWpGaD
Vidarabine—ADORA2A—Circadian rythm related genes—JUN—lung cancer	7.43e-05	0.000842	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by GPCR—GNG11—lung cancer	7.36e-05	0.000834	CbGpPWpGaD
Vidarabine—ADK—Metabolism—TYMS—lung cancer	7.34e-05	0.000831	CbGpPWpGaD
Vidarabine—ADORA2A—GPCR downstream signaling—ADCY1—lung cancer	7.28e-05	0.000826	CbGpPWpGaD
Vidarabine—ADA—Metabolism—ENO1—lung cancer	7.25e-05	0.000822	CbGpPWpGaD
Vidarabine—ADK—Metabolism—GSTM1—lung cancer	7.25e-05	0.000822	CbGpPWpGaD
Vidarabine—ADORA2A—Class A/1 (Rhodopsin-like receptors)—POMC—lung cancer	7.25e-05	0.000821	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by NGF—MAP2K1—lung cancer	7.24e-05	0.000821	CbGpPWpGaD
Vidarabine—Urticaria—Doxorubicin—lung cancer	7.22e-05	0.00042	CcSEcCtD
Vidarabine—ADORA2A—Signaling by NGF—PIK3CD—lung cancer	7.2e-05	0.000815	CbGpPWpGaD
Vidarabine—ADORA2A—Circadian rythm related genes—PTEN—lung cancer	7.19e-05	0.000814	CbGpPWpGaD
Vidarabine—ADORA2A—NGF signalling via TRKA from the plasma membrane—CDKN1A—lung cancer	7.06e-05	0.0008	CbGpPWpGaD
Vidarabine—ADORA2A—NGF signalling via TRKA from the plasma membrane—PTEN—lung cancer	7.05e-05	0.000799	CbGpPWpGaD
Vidarabine—Dizziness—Methotrexate—lung cancer	6.94e-05	0.000403	CcSEcCtD
Vidarabine—ADK—Metabolism—CYP1A1—lung cancer	6.88e-05	0.000779	CbGpPWpGaD
Vidarabine—ADORA2A—Circadian rythm related genes—EP300—lung cancer	6.85e-05	0.000777	CbGpPWpGaD
Vidarabine—ADK—Metabolism—ERCC2—lung cancer	6.82e-05	0.000773	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—COL4A2—lung cancer	6.8e-05	0.000771	CbGpPWpGaD
Vidarabine—ADORA2A—GPCR downstream signaling—PTHLH—lung cancer	6.77e-05	0.000767	CbGpPWpGaD
Vidarabine—Hypersensitivity—Doxorubicin—lung cancer	6.7e-05	0.000389	CcSEcCtD
Vidarabine—Vomiting—Methotrexate—lung cancer	6.68e-05	0.000388	CcSEcCtD
Vidarabine—ADORA2A—Signaling Pathways—GIPR—lung cancer	6.63e-05	0.000751	CbGpPWpGaD
Vidarabine—Rash—Methotrexate—lung cancer	6.62e-05	0.000385	CcSEcCtD
Vidarabine—ADORA2A—Signaling by GPCR—ADCY1—lung cancer	6.62e-05	0.00075	CbGpPWpGaD
Vidarabine—Dermatitis—Methotrexate—lung cancer	6.61e-05	0.000384	CcSEcCtD
Vidarabine—Headache—Methotrexate—lung cancer	6.58e-05	0.000382	CcSEcCtD
Vidarabine—ADORA2A—NGF signalling via TRKA from the plasma membrane—SRC—lung cancer	6.53e-05	0.000741	CbGpPWpGaD
Vidarabine—Asthenia—Doxorubicin—lung cancer	6.52e-05	0.000379	CcSEcCtD
Vidarabine—ADA—Metabolism—CYP2E1—lung cancer	6.51e-05	0.000737	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by GPCR—PPP2R1B—lung cancer	6.45e-05	0.000731	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by NGF—MDM2—lung cancer	6.45e-05	0.000731	CbGpPWpGaD
Vidarabine—ADA—Metabolism—NQO1—lung cancer	6.43e-05	0.000729	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by NGF—RAF1—lung cancer	6.42e-05	0.000728	CbGpPWpGaD
Vidarabine—ADORA2A—GPCR downstream signaling—ANXA1—lung cancer	6.37e-05	0.000722	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by NGF—ERBB2—lung cancer	6.36e-05	0.00072	CbGpPWpGaD
Vidarabine—ADORA2A—NGF signalling via TRKA from the plasma membrane—STAT3—lung cancer	6.3e-05	0.000714	CbGpPWpGaD
Vidarabine—ADORA2A—NGF signalling via TRKA from the plasma membrane—NRAS—lung cancer	6.29e-05	0.000712	CbGpPWpGaD
Vidarabine—DPP4—Metabolism of proteins—CXCL8—lung cancer	6.27e-05	0.000711	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by NGF—MTOR—lung cancer	6.27e-05	0.000711	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by NGF—PIK3CB—lung cancer	6.27e-05	0.000711	CbGpPWpGaD
Vidarabine—Nausea—Methotrexate—lung cancer	6.24e-05	0.000362	CcSEcCtD
Vidarabine—Adenosine triphosphate—ABCB1—lung cancer	6.19e-05	0.00723	CrCbGaD
Vidarabine—ADORA2A—Signaling Pathways—SDC4—lung cancer	6.19e-05	0.000701	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by GPCR—PTHLH—lung cancer	6.15e-05	0.000697	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—DUSP3—lung cancer	6.06e-05	0.000687	CbGpPWpGaD
Vidarabine—ADORA2A—GPCR downstream signaling—APP—lung cancer	6.04e-05	0.000684	CbGpPWpGaD
Vidarabine—ADORA2A—NGF signalling via TRKA from the plasma membrane—MAPK3—lung cancer	6.02e-05	0.000682	CbGpPWpGaD
Vidarabine—Dizziness—Doxorubicin—lung cancer	6.01e-05	0.000349	CcSEcCtD
Vidarabine—ADORA2A—Signaling Pathways—RHEB—lung cancer	5.95e-05	0.000674	CbGpPWpGaD
Vidarabine—ADK—Metabolism—APOA1—lung cancer	5.9e-05	0.000668	CbGpPWpGaD
Vidarabine—ADA—Metabolism—STK11—lung cancer	5.8e-05	0.000657	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by GPCR—ANXA1—lung cancer	5.78e-05	0.000655	CbGpPWpGaD
Vidarabine—Vomiting—Doxorubicin—lung cancer	5.78e-05	0.000336	CcSEcCtD
Vidarabine—ADORA2A—Signaling by NGF—CASP3—lung cancer	5.77e-05	0.000654	CbGpPWpGaD
Vidarabine—Rash—Doxorubicin—lung cancer	5.73e-05	0.000333	CcSEcCtD
Vidarabine—Dermatitis—Doxorubicin—lung cancer	5.73e-05	0.000333	CcSEcCtD
Vidarabine—ADORA2A—NGF signalling via TRKA from the plasma membrane—EGFR—lung cancer	5.73e-05	0.000649	CbGpPWpGaD
Vidarabine—Headache—Doxorubicin—lung cancer	5.7e-05	0.000331	CcSEcCtD
Vidarabine—ADORA2A—Signaling Pathways—GRM8—lung cancer	5.64e-05	0.000639	CbGpPWpGaD
Vidarabine—ADORA2A—Class A/1 (Rhodopsin-like receptors)—CXCL8—lung cancer	5.61e-05	0.000635	CbGpPWpGaD
Vidarabine—ADORA2A—GPCR ligand binding—POMC—lung cancer	5.52e-05	0.000626	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by GPCR—APP—lung cancer	5.48e-05	0.000621	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—SKI—lung cancer	5.46e-05	0.000619	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by NGF—CDKN1A—lung cancer	5.43e-05	0.000616	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by NGF—PTEN—lung cancer	5.42e-05	0.000614	CbGpPWpGaD
Vidarabine—ADORA2A—NGF signalling via TRKA from the plasma membrane—KRAS—lung cancer	5.41e-05	0.000613	CbGpPWpGaD
Vidarabine—Nausea—Doxorubicin—lung cancer	5.4e-05	0.000314	CcSEcCtD
Vidarabine—ADK—Metabolism—PIK3CG—lung cancer	5.39e-05	0.00061	CbGpPWpGaD
Vidarabine—ADA—Metabolism—GSTP1—lung cancer	5.36e-05	0.000608	CbGpPWpGaD
Vidarabine—ADA—Metabolism—CAT—lung cancer	5.22e-05	0.000592	CbGpPWpGaD
Vidarabine—ADK—Metabolism—POMC—lung cancer	5.13e-05	0.000581	CbGpPWpGaD
Vidarabine—ADA—Metabolism—ABCB1—lung cancer	5.08e-05	0.000575	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by NGF—SRC—lung cancer	5.03e-05	0.00057	CbGpPWpGaD
Vidarabine—ADK—Metabolism—CREBBP—lung cancer	4.99e-05	0.000566	CbGpPWpGaD
Vidarabine—ADA—Metabolism—TYMS—lung cancer	4.99e-05	0.000565	CbGpPWpGaD
Vidarabine—ADORA2A—NGF signalling via TRKA from the plasma membrane—PIK3CA—lung cancer	4.97e-05	0.000563	CbGpPWpGaD
Vidarabine—ADA—Metabolism—GSTM1—lung cancer	4.93e-05	0.000559	CbGpPWpGaD
Vidarabine—ADORA2A—Circadian rythm related genes—TP53—lung cancer	4.9e-05	0.000556	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by NGF—STAT3—lung cancer	4.85e-05	0.000549	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by NGF—NRAS—lung cancer	4.84e-05	0.000548	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—PXN—lung cancer	4.74e-05	0.000537	CbGpPWpGaD
Vidarabine—ADK—Metabolism—PIK3CD—lung cancer	4.73e-05	0.000536	CbGpPWpGaD
Vidarabine—ADORA2A—GPCR downstream signaling—AVP—lung cancer	4.69e-05	0.000532	CbGpPWpGaD
Vidarabine—ADK—Metabolism—ALB—lung cancer	4.67e-05	0.00053	CbGpPWpGaD
Vidarabine—ADA—Metabolism—CYP1A1—lung cancer	4.67e-05	0.00053	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—OXTR—lung cancer	4.64e-05	0.000526	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—AKR1C1—lung cancer	4.64e-05	0.000526	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—GRP—lung cancer	4.64e-05	0.000526	CbGpPWpGaD
Vidarabine—ADA—Metabolism—ERCC2—lung cancer	4.64e-05	0.000525	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by NGF—MAPK3—lung cancer	4.63e-05	0.000525	CbGpPWpGaD
Vidarabine—ADORA2A—NGF signalling via TRKA from the plasma membrane—HRAS—lung cancer	4.6e-05	0.000521	CbGpPWpGaD
Vidarabine—ADORA2A—Circadian rythm related genes—IL6—lung cancer	4.49e-05	0.000509	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by NGF—EGFR—lung cancer	4.41e-05	0.000499	CbGpPWpGaD
Vidarabine—ADORA2A—NGF signalling via TRKA from the plasma membrane—IL6—lung cancer	4.4e-05	0.000499	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—GNG11—lung cancer	4.35e-05	0.000493	CbGpPWpGaD
Vidarabine—ADORA2A—GPCR ligand binding—CXCL8—lung cancer	4.27e-05	0.000484	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by GPCR—AVP—lung cancer	4.26e-05	0.000483	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by NGF—KRAS—lung cancer	4.16e-05	0.000472	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—VEGFC—lung cancer	4.14e-05	0.000469	CbGpPWpGaD
Vidarabine—ADK—Metabolism—PIK3CB—lung cancer	4.13e-05	0.000468	CbGpPWpGaD
Vidarabine—ADK—Metabolism—PTGS2—lung cancer	4.09e-05	0.000463	CbGpPWpGaD
Vidarabine—ADORA2A—NGF signalling via TRKA from the plasma membrane—AKT1—lung cancer	4.06e-05	0.00046	CbGpPWpGaD
Vidarabine—ADA—Metabolism—APOA1—lung cancer	4.01e-05	0.000454	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—ADCY1—lung cancer	3.91e-05	0.000443	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by NGF—PIK3CA—lung cancer	3.82e-05	0.000433	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—PPP2R1B—lung cancer	3.81e-05	0.000432	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—SMARCA4—lung cancer	3.81e-05	0.000432	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—HSPB1—lung cancer	3.67e-05	0.000416	CbGpPWpGaD
Vidarabine—ADA—Metabolism—PIK3CG—lung cancer	3.66e-05	0.000415	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—PTHLH—lung cancer	3.63e-05	0.000412	CbGpPWpGaD
Vidarabine—ADK—Metabolism—PTEN—lung cancer	3.57e-05	0.000404	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by NGF—HRAS—lung cancer	3.54e-05	0.000401	CbGpPWpGaD
Vidarabine—ADA—Metabolism—POMC—lung cancer	3.48e-05	0.000395	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—ANXA1—lung cancer	3.42e-05	0.000387	CbGpPWpGaD
Vidarabine—ADK—Metabolism—EP300—lung cancer	3.4e-05	0.000385	CbGpPWpGaD
Vidarabine—ADA—Metabolism—CREBBP—lung cancer	3.39e-05	0.000385	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by NGF—IL6—lung cancer	3.39e-05	0.000384	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—FLT1—lung cancer	3.31e-05	0.000375	CbGpPWpGaD
Vidarabine—ADORA2A—GPCR downstream signaling—PIK3CG—lung cancer	3.28e-05	0.000371	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—NOTCH3—lung cancer	3.24e-05	0.000367	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—APP—lung cancer	3.24e-05	0.000367	CbGpPWpGaD
Vidarabine—ADA—Metabolism—PIK3CD—lung cancer	3.22e-05	0.000365	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—FGF9—lung cancer	3.21e-05	0.000364	CbGpPWpGaD
Vidarabine—ADA—Metabolism—ALB—lung cancer	3.18e-05	0.00036	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by NGF—AKT1—lung cancer	3.12e-05	0.000354	CbGpPWpGaD
Vidarabine—ADORA2A—GPCR downstream signaling—POMC—lung cancer	3.12e-05	0.000354	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—JUNB—lung cancer	3.07e-05	0.000347	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by GPCR—PIK3CG—lung cancer	2.98e-05	0.000337	CbGpPWpGaD
Vidarabine—ADORA2A—GPCR downstream signaling—PIK3CD—lung cancer	2.88e-05	0.000326	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by GPCR—POMC—lung cancer	2.83e-05	0.000321	CbGpPWpGaD
Vidarabine—ADA—Metabolism—PIK3CB—lung cancer	2.8e-05	0.000318	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—STK11—lung cancer	2.78e-05	0.000316	CbGpPWpGaD
Vidarabine—ADA—Metabolism—PTGS2—lung cancer	2.78e-05	0.000315	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by GPCR—IL6R—lung cancer	2.76e-05	0.000313	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—FOXO3—lung cancer	2.69e-05	0.000305	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by GPCR—MAP2K1—lung cancer	2.63e-05	0.000298	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by GPCR—PIK3CD—lung cancer	2.62e-05	0.000296	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—AVP—lung cancer	2.52e-05	0.000285	CbGpPWpGaD
Vidarabine—ADK—Metabolism—PIK3CA—lung cancer	2.52e-05	0.000285	CbGpPWpGaD
Vidarabine—ADORA2A—GPCR downstream signaling—PIK3CB—lung cancer	2.51e-05	0.000285	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—IGF1R—lung cancer	2.42e-05	0.000275	CbGpPWpGaD
Vidarabine—ADA—Metabolism—PTEN—lung cancer	2.42e-05	0.000275	CbGpPWpGaD
Vidarabine—ADORA2A—GPCR downstream signaling—CXCL8—lung cancer	2.41e-05	0.000273	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—HES1—lung cancer	2.38e-05	0.00027	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by GPCR—RAF1—lung cancer	2.34e-05	0.000265	CbGpPWpGaD
Vidarabine—ADA—Metabolism—EP300—lung cancer	2.31e-05	0.000262	CbGpPWpGaD
Vidarabine—ADORA2A—GPCR downstream signaling—IL2—lung cancer	2.31e-05	0.000261	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by GPCR—PIK3CB—lung cancer	2.28e-05	0.000258	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by GPCR—CXCL8—lung cancer	2.19e-05	0.000248	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—ERBB3—lung cancer	2.18e-05	0.000247	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by GPCR—IL2—lung cancer	2.09e-05	0.000237	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—TERT—lung cancer	2.09e-05	0.000236	CbGpPWpGaD
Vidarabine—ADK—Metabolism—AKT1—lung cancer	2.05e-05	0.000233	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—FGFR1—lung cancer	2.03e-05	0.00023	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—HIF1A—lung cancer	2e-05	0.000226	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—APOA1—lung cancer	1.93e-05	0.000218	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—KDR—lung cancer	1.91e-05	0.000216	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—KIT—lung cancer	1.76e-05	0.000199	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—APC—lung cancer	1.76e-05	0.000199	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—PIK3CG—lung cancer	1.76e-05	0.000199	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by GPCR—NRAS—lung cancer	1.76e-05	0.000199	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—EGF—lung cancer	1.74e-05	0.000197	CbGpPWpGaD
Vidarabine—ADA—Metabolism—PIK3CA—lung cancer	1.71e-05	0.000194	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by GPCR—MAPK3—lung cancer	1.68e-05	0.000191	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—POMC—lung cancer	1.67e-05	0.00019	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—BRAF—lung cancer	1.65e-05	0.000187	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—IL6R—lung cancer	1.63e-05	0.000185	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—CREBBP—lung cancer	1.63e-05	0.000185	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by GPCR—EGFR—lung cancer	1.6e-05	0.000182	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—MAP2K1—lung cancer	1.56e-05	0.000176	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—PIK3CD—lung cancer	1.55e-05	0.000175	CbGpPWpGaD
Vidarabine—ADORA2A—GPCR downstream signaling—PIK3CA—lung cancer	1.53e-05	0.000173	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by GPCR—KRAS—lung cancer	1.51e-05	0.000171	CbGpPWpGaD
Vidarabine—ADA—Metabolism—AKT1—lung cancer	1.4e-05	0.000158	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by GPCR—PIK3CA—lung cancer	1.39e-05	0.000158	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—MDM2—lung cancer	1.38e-05	0.000157	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—RAF1—lung cancer	1.38e-05	0.000156	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—ERBB2—lung cancer	1.37e-05	0.000155	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—PIK3CB—lung cancer	1.35e-05	0.000153	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—MTOR—lung cancer	1.35e-05	0.000153	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—CXCL8—lung cancer	1.29e-05	0.000147	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by GPCR—HRAS—lung cancer	1.29e-05	0.000146	CbGpPWpGaD
Vidarabine—ADORA2A—GPCR downstream signaling—AKT1—lung cancer	1.25e-05	0.000142	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—CASP3—lung cancer	1.24e-05	0.00014	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—IL2—lung cancer	1.24e-05	0.00014	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by GPCR—IL6—lung cancer	1.23e-05	0.000139	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—CCND1—lung cancer	1.21e-05	0.000137	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—JUN—lung cancer	1.2e-05	0.000136	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—MMP9—lung cancer	1.17e-05	0.000133	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—CDKN1A—lung cancer	1.17e-05	0.000132	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—PTEN—lung cancer	1.16e-05	0.000132	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by GPCR—AKT1—lung cancer	1.14e-05	0.000129	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—EP300—lung cancer	1.11e-05	0.000126	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—SRC—lung cancer	1.08e-05	0.000122	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—VEGFA—lung cancer	1.05e-05	0.000119	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—STAT3—lung cancer	1.04e-05	0.000118	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—NRAS—lung cancer	1.04e-05	0.000118	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—MAPK3—lung cancer	9.95e-06	0.000113	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—MYC—lung cancer	9.67e-06	0.00011	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—EGFR—lung cancer	9.46e-06	0.000107	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—KRAS—lung cancer	8.94e-06	0.000101	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—PIK3CA—lung cancer	8.21e-06	9.31e-05	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—TP53—lung cancer	7.94e-06	9e-05	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—HRAS—lung cancer	7.6e-06	8.61e-05	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—IL6—lung cancer	7.27e-06	8.24e-05	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—AKT1—lung cancer	6.71e-06	7.6e-05	CbGpPWpGaD
